In this episode, Jacques covers papers from January 2021 on the mechanisms of APP processing in Alzheimer's disease and strategies to alter amyloid-beta production. Learn something new as we explore pathways associated with increased amyloid-beta production, the development of BACE inhibitors and recent clinical trial findings!

Elyn is back with more on vascular contributions to Alzheimer disease. Tune in to hear about clinical studies connecting the vasculature to the AD pathology, mechanistic studies about amyloid clearance and deposition into cerebral vessles, and much more - all from papers published in January 2021!

Sections in this episode:

Clinical Studies - Connecting the Vasculature to the AD Pathology (3.20)

Cerebral Amyloid Angiopathy (14.36)

Cerebral Blood Flow (27.23)

Endothelial/Blood-Brain Barrier Damage (30.37)

In this episode on epidemiological studies published in January 2021, Naila will take you through a range of risk factors of AD, including cardiovascular disease, diabetes, other comorbidities, environmental factors, and a few protective factors. There’s a lot of information packed into 21 papers, so you’re sure to feel accomplished after!

Sections in this episode:

Prevalence (1:47)

Comorbidities (4:45)

Comorbidities - Neuro/Psychiatric conditions (20:52)

Environmental Factors (28:10)

Protective Factors (34:16)

In this episode, Courtney will take you through the papers published on ApoE in Alzheimer's disease from January 2021. The topics covered include the role of ApoE on cognitive function, the impact of ApoE on biomarkers and the molecular mechanisms ApoE impacts. Be sure to tune in for all things ApoE!!

Sections in this episode:

Cognitive Function (2.00) 

Impact of ApoE on Biomarkers (9.43) 

Molecular Mechanisms (12.43)

In the first episode of our January 2021 series, Anusha will be guiding you through papers that traverse topics within neuroprotection in AD models, including therapies that target A-beta toxicity, glutamate excito-toxicity, and novel therapeutic approaches. We hope you get excited - within reason!

Sections in this episode:

Amyloid-beta toxicity and glutamate excito-toxicity (2:03)

Novel therapeutic strategies (9:30)

In this episode, Courtney covers Part 2 of the papers published in September of 2020 on cognitive testing as a diagnostic tool. The topics in this part cover a wide array of topics including brain wave techniques, gait analysis, facial recognition, neuropsychiatric symptoms, and finally cognitive testing.

Sections:

1:56 Brain wave studies in Dementia (2 papers)

4:23 Gait (2 papers)

7:16 Facial Recognition and Facial structure (3 papers)

12:29 Neuropsychiatric symptoms in Dementia (5 papers)

19:39 Cognitive Testing for AD (4 papers)

This shorter episode on metabolic changes and hemodynamics covers a wide range of neuroimaging techniques, including FDG PET, MRI and CT. Judy will discuss the applications of these modalities in deep learning, AD diagnosis and more. Definitely worth a listen if you’re into neuroimaging!

Sections in this episode:

FTG PET papers - 1:02

MRI papers - 9:40

This episode covers recent papers that explore the underlying mechanisms of both protective and risk factors of Alzheimer’s disease. You’ll hear a little about how education, exercise and diet might reduce the risk of cognitive decline later in life, and a lot about the physiological and biochemical factors underlying high fat diets, diabetes, cardiovascular disease and exposure to environmental pollutants - with the occasional miscellaneous topic in between!

Sections in this episode:

1:35 Protective factors

7:50 Risk factors (diet, diabetes, cardiovascular)

26:16 Vitamin Deficiencies and AD

29:27 Environmental Exposures and AD

35:26 Miscellaneous

This episode, hosted by Naila, covers papers published in September 2020 that use cognitive testing as a diagnostic tool. These studies vary from validating and comparing existing tests, to refining them for specific applications, to correlating cognition with AD biomarkers. You’ll learn a bit about the variety of cognitive tests used, and how researchers are constantly building on existing tools to better predict the risk and progression of cognitive decline.

Sections:

Cognition & Imaging: 1.46

Validation & Refinement of Existing Tests: 6.30

Spatial & Facial Tests: 15.05

Specific Populations: 21.18

New Tools: 25.50

In this episode, Marcia will cover papers published in Sept 2020 on treatment development for AD with special focus on the tau protein. She discusses tau in its role as a microtubule-associated protein and the related use of microtubule-stabilizing agents in treating AD. She also talks about papers on immunotherapy, autophagy, and inhibiting tau hyperphosphorylation. Tune in to hear about all of this and more!